Human Complement Receptor Type 1/CD35 Is an Epstein-Barr Virus Receptor

Cell Reports

Volumn 3, Issue 2, 2013, Pages 371-385

  Ogembo, Javier G ^a,b   Kannan, Lakshmi ^a   Ghiran, Ionita ^a   Nicholson Weller, Anne ^a   Finberg, Robert W ^b   Tsokos, George C ^a   Fingeroth, Joyce D ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT COMPONENT C3D RECEPTOR; EPSTEIN BARR VIRUS ANTIGEN; GLYCOPROTEIN GP 220; GLYCOPROTEIN GP 350; HLA ANTIGEN CLASS 2; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS GLYCOPROTEIN; VIRUS VACCINE;

ARTICLE; B LYMPHOCYTE; BIOPHYSICS; CONTROLLED STUDY; ENZYME ACTIVITY; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; HUMAN; HUMAN CELL; MYELOID LEUKEMIA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; VIRAL TROPISM;

ANTIGENS, CD19; CELL LINE; HERPESVIRUS 4, HUMAN; HUMANS; K562 CELLS; MUTATION; PRECURSOR CELLS, B-LYMPHOID; PROTEIN BINDING; RECEPTORS, COMPLEMENT 3B; RECEPTORS, COMPLEMENT 3D; TEMPERATURE; TRANSFECTION; VIRAL MATRIX PROTEINS; VIRUS ATTACHMENT; VIRUS INTERNALIZATION;

HUMAN HERPESVIRUS 4;

EID: 84874260436     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2013.01.023     Document Type: Article

References (60)

1. Asokan R., Hua J., Young K.A., Gould H.J., Hannan J.P., Kraus D.M., Szakonyi G., Grundy G.J., Chen X.S., Crow M.K., Holers V.M. Characterization of human complement receptor type 2 (CR2/CD21) as a receptor for IFN-alpha: a potential role in systemic lupus erythematosus. J. Immunol. 2006, 177:383-394.
2. Birmingham D.J., Hebert L.A. CR1 and CR1-like: the primate immune adherence receptors. Immunol. Rev. 2001, 180:100-111.
3. Busse C., Feederle R., Schnölzer M., Behrends U., Mautner J., Delecluse H.J. Epstein-Barr viruses that express a CD21 antibody provide evidence that gp350's functions extend beyond B-cell surface binding. J. Virol. 2010, 84:1139-1147.
4. Calattini S., Sereti I., Scheinberg P., Kimura H., Childs R.W., Cohen J.I. Detection of EBV genomes in plasmablasts/plasma cells and non-B cells in the blood of most patients with EBV lymphoproliferative disorders by using Immuno-FISH. Blood 2010, 116:4546-4559.
5. Calender A., Cordier M., Billaud M., Lenoir G.M. Modulation of cellular gene expression in B lymphoma cells following in vitro infection by Epstein-Barr virus (EBV). Int. J. Cancer 1990, 46:658-663.
6. Chen C.H., Ghiran I., Beurskens F.J., Weaver G., Vincent J.A., Nicholson-Weller A., Klickstein L.B. Antibody CR1-2B11 recognizes a non-polymorphic epitope of human CR1 (CD35). Clin. Exp. Immunol. 2007, 148:546-554.
7. Choy E., Yelensky R., Bonakdar S., Plenge R.M., Saxena R., De Jager P.L., Shaw S.Y., Wolfish C.S., Slavik J.M., Cotsapas C., et al. Genetic analysis of human traits in vitro: drug response and gene expression in lymphoblastoid cell lines. PLoS Genet. 2008, 4:e1000287.
8. Cohen J.H., Fischer E., Kazatchkine M.D., Lenoir G.M., Lefevre-Delvincourt C., Revillard J.P. Expression of CR1 and CR2 complement receptors following Epstein-Barr virus infection of Burkitt's lymphoma cell lines. Scand. J. Immunol. 1987, 25:587-598.
9. Connolly S.A., Jackson J.O., Jardetzky T.S., Longnecker R. Fusing structure and function: a structural view of the herpesvirus entry machinery. Nat. Rev. Microbiol. 2011, 9:369-381.
10. Cordier-Bussat M., Billaud M., Calender A., Lenoir G.M. Epstein-Barr virus (EBV) nuclear-antigen-2-induced up-regulation of CD21 and CD23 molecules is dependent on a permissive cellular context. Int. J. Cancer 1993, 53:153-160.
11. Edson C.M., Thorley-Lawson D.A. Epstein-Barr virus membrane antigens: characterization, distribution, and strain differences. J. Virol. 1981, 39:172-184.
12. Einhorn L., Klein E. EBV infection of mitogen-stimulated human B lymphocytes. Int. J. Cancer 1981, 27:181-183.
13. Epstein M.A., Henle G., Achong B.G., Barr Y.M. Morphological and Biological Studies on a Virus in Cultured Lymphoblasts from Burkitt's Lymphoma. J. Exp. Med. 1965, 121:761-770.
14. Erdei A., Isaák A., Török K., Sándor N., Kremlitzka M., Prechl J., Bajtay Z. Expression and role of CR1 and CR2 on B and T lymphocytes under physiological and autoimmune conditions. Mol. Immunol. 2009, 46:2767-2773.
15. Ernberg I., Falk K., Hansson M. Progenitor and pre-B lymphocytes transformed by Epstein-Barr virus. Int. J. Cancer 1987, 39:190-197.
16. Faulkner G.C., Burrows S.R., Khanna R., Moss D.J., Bird A.G., Crawford D.H. X-Linked agammaglobulinemia patients are not infected with Epstein-Barr virus: implications for the biology of the virus. J. Virol. 1999, 73:1555-1564.
17. Fingeroth J.D. Comparative structure and evolution of murine CR2. The homolog of the human C3d/EBV receptor (CD21). J. Immunol. 1990, 144:3458-3467.
18. Fingeroth J.D., Weis J.J., Tedder T.F., Strominger J.L., Biro P.A., Fearon D.T. Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. Proc. Natl. Acad. Sci. USA 1984, 81:4510-4514.
19. Fingeroth J.D., Benedict M.A., Levy D.N., Strominger J.L. Identification of murine complement receptor type 2. Proc. Natl. Acad. Sci. USA 1989, 86:242-246.
20. Frade R., Barel M., Ehlin-Henriksson B., Klein G. gp140, the C3d receptor of human B lymphocytes, is also the Epstein-Barr virus receptor. Proc. Natl. Acad. Sci. USA 1985, 82:1490-1493.
21. Ghiran I., Barbashov S.F., Klickstein L.B., Tas S.W., Jensenius J.C., Nicholson-Weller A. Complement receptor 1/CD35 is a receptor for mannan-binding lectin. J. Exp. Med. 2000, 192:1797-1808.
22. Ghiran I., Glodek A.M., Weaver G., Klickstein L.B., Nicholson-Weller A. Ligation of erythrocyte CR1 induces its clustering in complex with scaffolding protein FAP-1. Blood 2008, 112:3465-3473.
23. Gross A.J., Hochberg D., Rand W.M., Thorley-Lawson D.A. EBV and systemic lupus erythematosus: a new perspective. J. Immunol. 2005, 174:6599-6607.
24. Haywood A.M. Virus receptors: binding, adhesion strengthening, and changes in viral structure. J. Virol. 1994, 68:1-5.
25. Holland J.J., McLaren L.C. The mammalian cell-virus relationship. II. Adsorption, reception, and eclipse of poliovirus by HeLa cells. J. Exp. Med. 1959, 109:487-504.
26. Hutt-Fletcher L.M. Epstein-Barr virus entry. J. Virol. 2007, 81:7825-7832.
27. Isaák A., Gergely P., Szekeres Z., Prechl J., Poór G., Erdei A., Gergely J. Physiological up-regulation of inhibitory receptors Fc gamma RII and CR1 on memory B cells is lacking in SLE patients. Int. Immunol. 2008, 20:185-192.
28. James J.A., Kaufman K.M., Farris A.D., Taylor-Albert E., Lehman T.J., Harley J.B. An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. J. Clin. Invest. 1997, 100:3019-3026.
29. Klickstein L.B., Bartow T.J., Miletic V., Rabson L.D., Smith J.A., Fearon D.T. Identification of distinct C3b and C4b recognition sites in the human C3b/C4b receptor (CR1, CD35) by deletion mutagenesis. J. Exp. Med. 1988, 168:1699-1717.
30. Kovacs J.M., Hannan J.P., Eisenmesser E.Z., Holers V.M. Biophysical investigations of complement receptor 2 (CD21 and CR2)-ligand interactions reveal amino acid contacts unique to each receptor-ligand pair. J. Biol. Chem. 2010, 285:27251-27258.
31. Krushkal J., Bat O., Gigli I. Evolutionary relationships among proteins encoded by the regulator of complement activation gene cluster. Mol. Biol. Evol. 2000, 17:1718-1730.
32. Krych-Goldberg M., Atkinson J.P. Structure-function relationships of complement receptor type 1. Immunol. Rev. 2001, 180:112-122.
33. Kudoh A., Fujita M., Kiyono T., Kuzushima K., Sugaya Y., Izuta S., Nishiyama Y., Tsurumi T. Reactivation of lytic replication from B cells latently infected with Epstein-Barr virus occurs with high S-phase cyclin-dependent kinase activity while inhibiting cellular DNA replication. J. Virol. 2003, 77:851-861.
34. Larochelle B., Flamand L., Gourde P., Beauchamp D., Gosselin J. Epstein-Barr virus infects and induces apoptosis in human neutrophils. Blood 1998, 92:291-299.
35. LeibundGut-Landmann S., Waldburger J.M., Krawczyk M., Otten L.A., Suter T., Fontana A., Acha-Orbea H., Reith W. Mini-review: specificity and expression of CIITA, the master regulator of MHC class II genes. Eur. J. Immunol. 2004, 34:1513-1525.
36. Li Q., Spriggs M.K., Kovats S., Turk S.M., Comeau M.R., Nepom B., Hutt-Fletcher L.M. Epstein-Barr virus uses HLA class II as a cofactor for infection of B lymphocytes. J. Virol. 1997, 71:4657-4662.
37. Miyashita E.M., Yang B., Babcock G.J., Thorley-Lawson D.A. Identification of the site of Epstein-Barr virus persistence in vivo as a resting B cell. J. Virol. 1997, 71:4882-4891.
38. Moore M.D., Cooper N.R., Tack B.F., Nemerow G.R. Molecular cloning of the cDNA encoding the Epstein-Barr virus/C3d receptor (complement receptor type 2) of human B lymphocytes. Proc. Natl. Acad. Sci. USA 1987, 84:9194-9198.
39. Nemerow G.R., Cooper N.R. Early events in the infection of human B lymphocytes by Epstein-Barr virus: the internalization process. Virology 1984, 132:186-198.
40. Nemerow G.R., Wolfert R., McNaughton M.E., Cooper N.R. Identification and characterization of the Epstein-Barr virus receptor on human B lymphocytes and its relationship to the C3d complement receptor (CR2). J. Virol. 1985, 55:347-351.
41. Prota A.E., Sage D.R., Stehle T., Fingeroth J.D. The crystal structure of human CD21: implications for Epstein-Barr virus and C3d binding. Proc. Natl. Acad. Sci. USA 2002, 99:10641-10646.
42. Rickinson A.B., Kieff E. Epstein-Barr virus. Fields Virology 2007, 2655-2700. Lippiincott, Williams & Wilkins, Philadelphia. D.M. Knipe, P.M. Howley (Eds.).
43. Riley J.L., Westerheide S.D., Price J.A., Brown J.A., Boss J.M. Activation of class II MHC genes requires both the X box region and the class II transactivator (CIITA). Immunity 1995, 2:533-543.
44. Roome A.J., Reading C.L. Frequency of B-lymphocyte transformation by Epstein-Barr virus decreases with entry into the cell cycle. Immunology 1987, 60:195-201.
45. Roozendaal R., Carroll M.C. Complement receptors CD21 and CD35 in humoral immunity. Immunol. Rev. 2007, 219:157-166.
46. Sashihara J., Burbelo P.D., Savoldo B., Pierson T.C., Cohen J.I. Human antibody titers to Epstein-Barr Virus (EBV) gp350 correlate with neutralization of infectivity better than antibody titers to EBV gp42 using a rapid flow cytometry-based EBV neutralization assay. Virology 2009, 391:249-256.
47. Schlossman S.F., Boumsell L., Gilks W., Harlan J.M., Kishimoto T., Morimoto C., Ritz J., Shaw S., Silverstrin R., Springer T., et al. Leukocyte Typing V: White Cell Differentiation Antigens 1995, Volume 1. Oxford University Press, NY.
48. Shaw P.L., Kirschner A.N., Jardetzky T.S., Longnecker R. Characteristics of Epstein-Barr virus envelope protein gp42. Virus Genes 2010, 40:307-319.
49. Spadafora C., Awandare G.A., Kopydlowski K.M., Czege J., Moch J.K., Finberg R.W., Tsokos G.C., Stoute J.A. Complement receptor 1 is a sialic acid-independent erythrocyte receptor of Plasmodium falciparum. PLoS Pathog. 2010, 6:e1000968.
50. Speck P., Longnecker R. Epstein-Barr virus (EBV) infection visualized by EGFP expression demonstrates dependence on known mediators of EBV entry. Arch. Virol. 1999, 144:1123-1137.
51. Tanner J., Weis J., Fearon D., Whang Y., Kieff E. Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis. Cell 1987, 50:203-213.
52. Tanner J., Whang Y., Sample J., Sears A., Kieff E. Soluble gp350/220 and deletion mutant glycoproteins block Epstein-Barr virus adsorption to lymphocytes. J. Virol. 1988, 62:4452-4464.
53. Tedder T.F., Inaoki M., Sato S. The CD19-CD21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity. Immunity 1997, 6:107-118.
54. Tham W.H., Schmidt C.Q., Hauhart R.E., Guariento M., Tetteh-Quarcoo P.B., Lopaticki S., Atkinson J.P., Barlow P.N., Cowman A.F. Plasmodium falciparum uses a key functional site in complement receptor type-1 for invasion of human erythrocytes. Blood 2011, 118:1923-1933.
55. Thiel J., Kimmig L., Salzer U., Grudzien M., Lebrecht D., Hagena T., Draeger R., Völxen N., Bergbreiter A., Jennings S., et al. Genetic CD21 deficiency is associated with hypogammaglobulinemia. J. Allergy Clin. Immunol. 2012, 129:801-810.
56. Tsokos G.C., Thyphronitis G., Jack R.M., Finkelman F.D. Ligand-loaded but not free complement receptors for C3b/C4b and C3d co-cap with cross-linked B cell surface IgM and IgD. J. Immunol. 1988, 141:1261-1266.
57. Tuveson D.A., Ahearn J.M., Matsumoto A.K., Fearon D.T. Molecular interactions of complement receptors on B lymphocytes: a CR1/CR2 complex distinct from the CR2/CD19 complex. J. Exp. Med. 1991, 173:1083-1089.
58. Wang F., Gregory C., Sample C., Rowe M., Liebowitz D., Murray R., Rickinson A., Kieff E. Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J. Virol. 1990, 64:2309-2318.
59. Weiss L., Delfraissy J.F., Vazquez A., Wallon C., Galanaud P., Kazatchkine M.D. Monoclonal antibodies to the human C3b/C4b receptor (CR1) enhance specific B cell differentiation. J. Immunol. 1987, 138:2988-2993.
60. Zychlinska M., Herrmann H., Zimber-Strobl U., Hammerschmidt W. Restricted expression of Epstein-Barr virus latent genes in murine B cells derived from embryonic stem cells. PLoS One 2008, 3:e1996.